PROTACs

PROTACs includes companies using targeted protein degradation to eliminate disease-causing proteins rather than simply inhibit them. This category is followed closely because it represents a differentiated drug-design strategy with potential advantages in select oncology and immunology settings.

Why watch PROTACs

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest PROTACs news

The latest feed items from companies currently grouped under PROTACs.

1. 01
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

   Source: Nurix Therapeutics

2. 02
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

   Source: Nurix Therapeutics

3. 03
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

   Source: Nurix Therapeutics

4. 04
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics to Participate in Upcoming Investor Conferences

   Source: Nurix Therapeutics

5. 05
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

   Source: Nurix Therapeutics

6. 06
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

   Source: Nurix Therapeutics

7. 07
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

   Source: Nurix Therapeutics

8. 08
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

   Source: Nurix Therapeutics

9. 09
   2026-06-25 13:46 EST

   NRIXNurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

   Source: Nurix Therapeutics

10. 10
    2026-06-25 13:46 EST

    NRIXNurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

    Source: Nurix Therapeutics

11. 11
    2026-06-25 13:46 EST

    NRIXNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

    Source: Nurix Therapeutics

12. 12
    2026-06-25 13:46 EST

    NRIXNurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

    Source: Nurix Therapeutics

13. 13
    2026-06-25 13:46 EST

    NRIXNurix Therapeutics to Participate in Upcoming Investor Conference

    Source: Nurix Therapeutics

14. 14
    2026-06-25 13:46 EST

    NRIXNurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

    Source: Nurix Therapeutics

15. 15
    2026-06-25 13:46 EST

    NRIXNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

    Source: Nurix Therapeutics

Companies in PROTACs

3 companies tagged with PROTACs.

Frequently Asked Questions